CHRISTI JAMESON: Open Payments
NPI 1780026377 · POPLAR BLUFF, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,550 in 79 payments from 10 companies in 2025. Trend: 2023 $1,946 · 2024 $1,763 · 2025 $1,550
Food & beverage: $1,550
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $383 |
| Alkermes, Inc. | 17 | $328 |
| Janssen Pharmaceuticals, Inc | 8 | $263 |
| Teva Pharmaceuticals USA, Inc. | 8 | $192 |
| E.R. Squibb & Sons, L.L.C. | 9 | $159 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| Lundbeck LLC | 3 | $50 |
| Vanda Pharmaceuticals Inc. | 2 | $40 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
| Braeburn Inc. | 1 | $27 |
Products named: VRAYLAR, ARISTADA, INVEGA SUSTENNA, UZEDY, COBENFY, REXULTI, FANAPT, CAPLYTA.
Industry payments across MO — which companies pay providers there.
